|Bid||0.2550 x N/A|
|Ask||0.2600 x N/A|
|Day's Range||0.2550 - 0.2550|
|52 Week Range||0.2500 - 0.6700|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Subscribe to Yahoo Finance Plus to view Fair Value for ILA.AXLearn more
To find a multi-bagger stock, what are the underlying trends we should look for in a business? In a perfect world, we'd like to see a company investing more capital
Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA) is pleased to announce that a key patent relating to the Company's lead program, ISLA-101, has been granted by the United States Patent & Trademark Office. ISLA-101 is a drug with a very well-known safety profile, being repurposed for mosquito borne viruses.
Australian antiviral drug development company, Island Pharmaceuticals (Island) is set to list on the Australian Securities Exchange (ASX) today after raising A$7.5 million through its Initial Public Offer (IPO) which was significantly oversubscribed.